Ben R. Taylor
CIK: 0001712276
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
RECURSION PHARMACEUTICALS, INC.
Discretionary Trading P&L
Holdings
Transaction History (29 total)
- Sep 15, 2026RXRX
RECURSION PHARMACEUTICALS, INC.
Tax Payment(F)Direct5.4K shares at avg. $3.41$18K - Aug 17, 2026RXRX
RECURSION PHARMACEUTICALS, INC.
Tax Payment(F)Direct25K shares at avg. $3.16$79K - Jun 15, 2026RXRX
RECURSION PHARMACEUTICALS, INC.
Tax Payment(F)Direct5.4K shares at avg. $3.15$17K - May 15, 2026RXRX
RECURSION PHARMACEUTICALS, INC.
Tax Payment(F)Direct25K shares at avg. $3.04$76K - Apr 6, 2026RXRX
RECURSION PHARMACEUTICALS, INC.
Tax Payment(F)Direct48K shares at avg. $3.11$149K - Mar 17, 2026RXRX
RECURSION PHARMACEUTICALS, INC.
Sale(S)Direct8K shares at avg. $3.39$27K - Mar 16, 2026RXRX
RECURSION PHARMACEUTICALS, INC.
Tax Payment(F)Direct7.1K shares at avg. $3.42$24K - Feb 18, 2026RXRX
RECURSION PHARMACEUTICALS, INC.
Sale(S)Direct13.4K shares at avg. $3.08$41K - Feb 17, 2026RXRX
RECURSION PHARMACEUTICALS, INC.
Tax Payment(F)Direct11.9K shares at avg. $3.49$42K - Feb 6, 2026RXRX
RECURSION PHARMACEUTICALS, INC.
Award(A)Direct24.3K shares- - Feb 6, 2026RXRX
RECURSION PHARMACEUTICALS, INC.
Tax Payment(F)Direct11.4K shares at avg. $3.98$45K - Feb 6, 2026RXRX
RECURSION PHARMACEUTICALS, INC.
Award(A)Direct446.3K shares- - Dec 29, 2025RXRX
RECURSION PHARMACEUTICALS, INC.
Sale(S)Direct21.4K shares at avg. $4.18$89K - Dec 15, 2025RXRX
RECURSION PHARMACEUTICALS, INC.
Tax Payment(F)Direct7.1K shares at avg. $4.33$31K - Nov 25, 2025RXRX
RECURSION PHARMACEUTICALS, INC.
Tax Payment(F)Direct2.3K shares at avg. $4.03$9K - Nov 17, 2025RXRX
RECURSION PHARMACEUTICALS, INC.
Tax Payment(F)Direct11.9K shares at avg. $4.14$49K - Sep 15, 2025RXRX
RECURSION PHARMACEUTICALS, INC.
Tax Payment(F)Direct7.1K shares at avg. $4.83$34K - Aug 15, 2025RXRX
RECURSION PHARMACEUTICALS, INC.
Tax Payment(F)Direct11.9K shares at avg. $5.64$67K - Jun 16, 2025RXRX
RECURSION PHARMACEUTICALS, INC.
Tax Payment(F)Direct7.1K shares at avg. $4.92$35K - May 15, 2025RXRX
RECURSION PHARMACEUTICALS, INC.
Tax Payment(F)Direct11.9K shares at avg. $4.25$51K - Apr 1, 2025RXRX
RECURSION PHARMACEUTICALS, INC.
Tax Payment(F)Direct26.6K shares at avg. $5.09$135K - Mar 17, 2025RXRX
RECURSION PHARMACEUTICALS, INC.
Tax Payment(F)Direct7.1K shares at avg. $6.84$48K - Feb 18, 2025RXRX
RECURSION PHARMACEUTICALS, INC.
Tax Payment(F)Direct10.9K shares at avg. $10.64$116K - Feb 3, 2025RXRX
RECURSION PHARMACEUTICALS, INC.
Tax Payment(F)Direct6.5K shares at avg. $7.25$47K - Feb 3, 2025RXRX
RECURSION PHARMACEUTICALS, INC.
Award(A)Direct13.9K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Sep 15, 2026 | RXRX RECURSION PHARMACEUTICALS, INC. | Tax Payment(F) | 5,396 | $3.41 | $18,400 | Direct |
| Aug 17, 2026 | RXRX RECURSION PHARMACEUTICALS, INC. | Tax Payment(F) | 25,018 | $3.16 | $79,057 | Direct |
| Jun 15, 2026 | RXRX RECURSION PHARMACEUTICALS, INC. | Tax Payment(F) | 5,396 | $3.15 | $16,997 | Direct |
| May 15, 2026 | RXRX RECURSION PHARMACEUTICALS, INC. | Tax Payment(F) | 25,018 | $3.04 | $76,055 | Direct |
| Apr 6, 2026 | RXRX RECURSION PHARMACEUTICALS, INC. | Tax Payment(F) | 48,028 | $3.11 | $149,367 | Direct |
| Mar 17, 2026 | RXRX RECURSION PHARMACEUTICALS, INC. | Sale(S) | 7,956 | $3.39 | $26,971 | Direct |
| Mar 16, 2026 | RXRX RECURSION PHARMACEUTICALS, INC. | Tax Payment(F) | 7,075 | $3.42 | $24,197 | Direct |
| Feb 18, 2026 | RXRX RECURSION PHARMACEUTICALS, INC. | Sale(S) | 13,426 | $3.08 | $41,352 | Direct |
| Feb 17, 2026 | RXRX RECURSION PHARMACEUTICALS, INC. | Tax Payment(F) | 11,908 | $3.49 | $41,559 | Direct |
| Feb 6, 2026 | RXRX RECURSION PHARMACEUTICALS, INC. | Award(A) | 24,254 | - | $0 | Direct |
| Feb 6, 2026 | RXRX RECURSION PHARMACEUTICALS, INC. | Tax Payment(F) | 11,400 | $3.98 | $45,372 | Direct |
| Feb 6, 2026 | RXRX RECURSION PHARMACEUTICALS, INC. | Award(A) | 446,279 | - | $0 | Direct |
| Dec 29, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | Sale(S) | 21,383 | $4.18 | $89,381 | Direct |
| Dec 15, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | Tax Payment(F) | 7,057 | $4.33 | $30,557 | Direct |
| Nov 25, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | Tax Payment(F) | 2,271 | $4.03 | $9,152 | Direct |
| Nov 17, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | Tax Payment(F) | 11,908 | $4.14 | $49,299 | Direct |
| Sep 15, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | Tax Payment(F) | 7,057 | $4.83 | $34,085 | Direct |
| Aug 15, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | Tax Payment(F) | 11,908 | $5.64 | $67,161 | Direct |
| Jun 16, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | Tax Payment(F) | 7,057 | $4.92 | $34,720 | Direct |
| May 15, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | Tax Payment(F) | 11,908 | $4.25 | $50,609 | Direct |
| Apr 1, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | Tax Payment(F) | 26,571 | $5.09 | $135,379 | Direct |
| Mar 17, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | Tax Payment(F) | 7,057 | $6.84 | $48,270 | Direct |
| Feb 18, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | Tax Payment(F) | 10,879 | $10.64 | $115,753 | Direct |
| Feb 3, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | Tax Payment(F) | 6,544 | $7.25 | $47,444 | Direct |
| Feb 3, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | Award(A) | 13,922 | - | - | Direct |
1-25 of 29 transactions
About Taylor Ben R
Taylor Ben R (SEC CIK 0001712276) files insider reports with the SEC as Chief Financial Officer of RECURSION PHARMACEUTICALS, INC. (RXRX).
Signal8 holds 23 ownership filings by Taylor Ben R (1 Form 3, 22 Form 4), filed between Dec 2, 2024 and Sep 16, 2026. Those filings report 29 transactions, from Dec 16, 2024 to Sep 15, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Taylor Ben R's filings is in SALT LAKE CITY, UT.
Recent filings by Taylor Ben R
- Sep 15, 2026: Tax withholding of RXRX shares (Form 4, code F).
- Aug 17, 2026: Tax withholding of RXRX shares (Form 4, code F).
- Jun 15, 2026: Tax withholding of RXRX shares (Form 4, code F).
- May 15, 2026: Tax withholding of RXRX shares (Form 4, code F).
- Apr 6, 2026: Tax withholding of RXRX shares (Form 4, code F).
Other insiders filing for RECURSION PHARMACEUTICALS, INC. (RXRX)
- Borgeson Blake, Director
- HERSHBERG ROBERT, Director
- Dar Zavain, Director
- Li Dean Y, Director
- Khan Najat, CEO and President
- Hallett David, Chief Scientific Officer